Stocks Comparison
HeartSciences vs Nakamoto: revenue, profit, margins and growth compared
HeartSciences brought in $4.3K of revenue in fiscal 2026, Nakamoto $1.8M in fiscal 2025. Revenue changed by -0.7% at HeartSciences and -33.0% at Nakamoto on the year before, so HeartSciences grew faster. HeartSciences kept -211,666.5% of its revenue as net profit, Nakamoto -2,867.6%.
Side by side, latest fiscal year
| HSCS | NAKA | |
|---|---|---|
| Fiscal year ended | FY2026 (April 30, 2026) | FY2025 (December 31, 2025) |
| Revenue | $4.3K | $1.8M |
| Revenue growth | -0.7% | -33.0% |
| Net income | -$9.1M | -$52.2M |
| Net margin | -211,666.5% | -2,867.6% |
| Free cash flow | -$7.4M | n/a |
| Free cash flow margin | -172,036.6% | n/a |
| Earnings per share (diluted) | -$3.48 | -$0.26 |
| Cash | $1.7M | $21.1M |
| Debt | n/a | n/a |
| Price to earnings | n/a | n/a |
| Market value | $17.3M | $173.9M |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #740 of 742 · Health care | #615 of 742 · Health care |
Over the years
Questions about HeartSciences and Nakamoto
Which is bigger by revenue, HeartSciences or Nakamoto?
Nakamoto is bigger by revenue: $1.8M in fiscal 2025, against $4.3K for HeartSciences in fiscal 2026.
Which keeps more of its revenue as profit, HeartSciences or Nakamoto?
HeartSciences had a net margin of -211,666.5% in fiscal 2026; Nakamoto had -2,867.6% in fiscal 2025.
Which grew revenue faster, HeartSciences or Nakamoto?
In their latest fiscal years revenue changed by -0.7% at HeartSciences and -33.0% at Nakamoto.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.